featured
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
JAMA Oncol 2022 Nov 17;[EPub Ahead of Print], AM Schram, N Colombo, E Arrowsmith, V Narayan, K Yonemori, G Scambia, A Zelnak, TM Bauer, N Jin, SV Ulahannan, M Colleoni, P Aftimos, MTA Donoghue, E Rosen, VA Rudneva, ML Telli, SM Domchek, MD Galsky, M Hoyle, C Chappey, R Stewart, JA Blake-Haskins, TA YapFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.